Clofibrate
Atromid-s (clofibrate) is a small molecule pharmaceutical. Clofibrate was first approved as Atromid-s on 1982-01-01. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. The pharmaceutical is active against peroxisome proliferator-activated receptor alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypercholesterolemia | — | D006937 | — |
| coronary artery disease | — | D003324 | I25.1 |
| hypertriglyceridemia | EFO_0004211 | D015228 | — |
| hyperlipoproteinemias | — | D006951 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
540 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | 3 | 3 | 14 | 8 | 5 | 32 |
| Healthy volunteers/patients | — | — | — | 15 | — | — | 1 | 12 | 28 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 4 | 4 | 7 | 15 |
| Pain | D010146 | EFO_0003843 | R52 | 2 | — | — | 5 | 6 | 13 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | 3 | 3 | 4 | 11 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 1 | 2 | 6 | 11 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | 2 | 4 | 2 | 10 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 3 | 4 | 1 | 9 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 2 | 3 | 4 | 9 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | 2 | 4 | 3 | 9 |
Show 92 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 17 | 18 | 4 | — | 4 | 39 |
| Carcinoma | D002277 | — | C80.0 | 10 | 18 | 7 | — | 2 | 34 |
| Lung neoplasms | D008175 | — | C34.90 | 6 | 16 | 6 | — | 1 | 26 |
| Neoplasms | D009369 | — | C80 | 14 | 13 | 1 | — | — | 25 |
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 11 | 6 | — | 1 | 21 |
| Syndrome | D013577 | — | — | 6 | 9 | 2 | — | 1 | 15 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | 10 | 2 | — | 1 | 14 |
| Adenocarcinoma | D000230 | — | — | 4 | 6 | 2 | — | 1 | 12 |
| Carcinoid tumor | D002276 | — | D3A.00 | 2 | 5 | 1 | — | 1 | 9 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 2 | 2 | 5 | — | 1 | 9 |
Show 57 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 17 | 10 | — | — | — | 21 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 8 | — | — | 1 | 14 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 6 | 5 | — | — | 1 | 10 |
| Leukemia | D007938 | — | C95 | 8 | 5 | — | — | — | 9 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 9 | 3 | — | — | — | 9 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 5 | 4 | — | — | 1 | 9 |
| Follicular lymphoma | D008224 | — | C82 | 8 | 4 | — | — | — | 9 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 6 | 3 | — | — | — | 7 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 7 | 2 | — | — | — | 7 |
| B-cell lymphoma | D016393 | — | — | 7 | 2 | — | — | — | 7 |
Show 154 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulpitis | D011671 | EFO_1001139 | K04.0 | 1 | — | — | — | 2 | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | 2 | — | — | — | — | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 2 | — | — | — | — | 2 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | 1 | 2 |
| Medullary carcinoma | D018276 | — | — | 2 | — | — | — | — | 2 |
| Hepatic insufficiency | D048550 | — | — | 2 | — | — | — | — | 2 |
| Tongue neoplasms | D014062 | EFO_0003871 | C02.9 | 2 | — | — | — | — | 2 |
| Laryngeal neoplasms | D007822 | EFO_0003817 | C32 | 2 | — | — | — | — | 2 |
Show 60 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Back pain | D001416 | — | M54 | — | — | — | — | 3 | 3 |
| Uterine cervical neoplasms | D002583 | — | — | — | — | — | — | 3 | 3 |
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | — | — | 3 | 3 |
| Flatfoot | D005413 | EFO_0003874 | M21.4 | — | — | — | — | 3 | 3 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | — | — | — | 2 | 2 |
| Cachexia | D002100 | — | R64 | — | — | — | — | 2 | 2 |
| Cardiac surgical procedures | D006348 | — | — | — | — | — | — | 2 | 2 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | — | — | — | 2 | 2 |
| Dry eye syndromes | D015352 | — | H04.12 | — | — | — | — | 2 | 2 |
| Biological availability | D001682 | — | — | — | — | — | — | 2 | 2 |
Show 116 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Clofibrate |
| INN | calcium clofibrate |
| Description | Clofibrate is the ethyl ester of clofibric acid. It has a role as an anticholesteremic drug, an antilipemic drug, a geroprotector and a PPARalpha agonist. It is an aromatic ether, a member of monochlorobenzenes and an ethyl ester. It is functionally related to a clofibric acid. |
| Classification | Small molecule |
| Drug class | antihyperlipidemics (clofibrate type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 637-07-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL565 |
| ChEBI ID | 3750 |
| PubChem CID | 2796 |
| DrugBank | DB00636 |
| UNII ID | TT85QFR500 (ChemIDplus, GSRS) |
Target
Agency Approved
PPARA
PPARA
Organism
Homo sapiens
Gene name
PPARA
Gene synonyms
NR1C1, PPAR
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor alpha
Protein synonyms
Nuclear receptor subfamily 1 group C member 1, peroxisome proliferative activated receptor, alpha
Uniprot ID
Mouse ortholog
Ppara (19013)
peroxisome proliferator-activated receptor alpha (P23204)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Clofibrate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 240,324 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
114 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use